rais po strong reiter buy
rais estim po break tafa valu
follow result management commentari reinforc oper strength
updat model po also updat model recent pemazyr approv
second line cca mutat increas assumpt follow-on
indic urotheli carcinoma follow recent doctor check assign
stand-alone valu tafasitamab doctor check indic excit
product r/r dlbcl impress respons rate ph l-mind studi
patient popul need effect therapi also adjust model
reflect approv tabrecta capmatinib recent quarterli call management highlight
diversifi commerci portfolio three product potenti launch
pemazyr approv april target doctor alreadi prescrib
may market partner nv nsclc mutat addit
near term launch await data pipelin program parsaclisib
limber jakafi life cycl extens ruxolitinib cream see also increas
net pipelin plug reflect valu limber parsaclisib
potenti label expans addit geographi market product includ
pemazyr tafasitamab retifanlimab antibodi covid program itacitinib
earli discoveri partnership potenti synergist bd reiter buy
rate po prev await develop emerg pipelin
addit clariti commerci opportun product launch
strong obscur tafasitamab deal recognit
report ep includ morphosys/tafa deal expens
oper line modest revenu beat across board
sale jakafi higher
guidanc reiter management indic advers covid
impact iclusig guidanc also reit
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
lo likelihood success
limber lead myeloprolif
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
incyt corpor biotechnolog
compani develop oral topic treatment
oncolog dermatolog indic
compani main asset jakafi mf pv
prepar launch two oncolog
medic also late stage
develop ruxolitinib cream
treatment ad vitiligo addit
rate buy view jakafi addit
revenu stream provid high valuat floor
earli stage pipelin littl clinic data
larg indic command larg amount
parsaclisib limber covid program updat
anticip catalyst parsaclisib inhibitor
citadel program three nhl data also anticip data
limber program bioavail /bioequiv once-daili rux potenti reduc
anemia expect combo parsaclisib enter pivot studi
pend posit proof-of-concept data view limber program
potenti sourc signific valu given model peak sale jakafi
current model rapid loss sale follow patent expir june await
long term safeti data rux cream ad clear nda submiss
continu expect rapid uptak broad usag behind firstlin steroid ad also
look updat inci program covid recent initi ph
po consist jakafi/jakavi ruxolitinib
cream pemigatinib tafasitamab olumi royalti
iclusig capmatinib royalti pipelin remaind net
cash appli wacc commercial-stag asset late-stag clinic
pipelin earlier stage clinic pipelin
upsid risk po posit data clinic trial pipelin better
expect result market asset addit updat earli stage
downsid risk po failur jakafi ruxolitinib cream meet
estim busi develop event investor view neg neg
data clinic trial
tazeen ahmad herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
